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Objectives. This study attempted to establish whether bam- 
iphylline, a selective antagonist of A t adenosine receptors, pre- 
vents the algogenic effects of adenosine in humans. 
Background. Experimental findings indicate that the sympa- 
thoexcitatory response licited by adenosine is mediated by AI 
receptors. 
Methods. An intrailiac infusion of increasing doses (from 125 to 
2,000 #g/min) of adenosine was given to 20 patients. Adenosine 
infusion was then repeated after intrailiac infusion of either 
bamiphylline or saline solution. In 14 other patients with angina, 
increasing doses of adenosine (from 108 to 1,728 #g/min) were 
infused into the left coronary artery. Adenosine infusion was then 
repeated after the intravenous infusion of either bamiphylline or 
placebo. Coronary blood flow velocity was monitored by a Doppler 
catheter. Data relative to pain severity are expressed as median 
and all other data as mean value -+ 1 SD. 
Results. Bamiphylline prolonged the time to pain onset caused 
by the intrailiac adenosine infusion from 444 -+ 96 to 749 -+ 120 s 
(p < 0.001) and reduced pain severity from 45 to 24 mm (p < 
0.01). After placebo infusion, the time to pain onset and pain 
severity were similar to that of baseline (428 -+ 112 vs. 430 -+ 104 s, 
p = 0.87 and 44 vs. 43 ram, p = 0.67, respectively). Bamiphylline 
prolonged the time to pain onset caused by intracoronary adeno- 
sine infusion from 519 -+ 128 to 603 -+ 146 s (p < 0.01) and 
reduced pain severity from 58 to 28 mm (p < 0.02). After placebo 
infusion, the time to pain onset and pain severity were similar to 
that at baseline (542 -+ 87 vs. 551 -+ 79 s, p = 0.14 and 55 vs. 
50 mm, p = 0.61). Maximal coronary blood flow velocities before 
and after bamiphylline administration were similar (47 -+ 22 vs. 
49 -+ 24 cm/s, p = 0.36) as well as before and after placebo 
administration (40 -+ 20 vs. 41 -+ 20 cm/s, p = 0.07). 
Conclusions. Bamiphylline reduces adenosine-induced muscu- 
lar and cardiac pain but does not affect adenosine-induced 
coronary vasodilation. These findings indicate that at the dose 
used in this study, bamiphylline does not detectably block vascu- 
lar A2-receptor-mediated a enosine ffects in humans, which 
suggests that the muscular and cardiac algogenic effects of 
adenosine are mediated mainly by A 1 receptors. 
(J Am Coil Cardiol 1995;25:251-7) 
Adenosine is a mediator of ischemic pain in humans (1-3). 
Local muscular ischemic-like pain can be provoked by 
adenosine injection into the brachial (4) or iliac (5) artery. 
Furthermore, in patients with ischemic heart disease, intra- 
coronary administration of adenosine licits angina pecto- 
ris-like pain indistinguishable from their habitual anginal 
pain in the absence of ischemic electrocardiographic (ECG) 
changes (2,3,5). The cardiac effects of adenosine are due to 
the stimulation of two classes of extracellular receptors, 
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subtypes  A 1 and A 2 (6-8). The stimulation of A t receptors, 
present in cardiomyocytes and perivascular sympathetic 
nerves (8,9), causes electrophysiologic effects (10) and 
inhibits the neuronal release of cateeholamines (8). The 
stimulation of A 2 receptors, present in endothelial and 
vascular smooth muscle cells, causes coronary vasodilation 
(11-14). Recent experimental investigations (15) suggest 
that adenosine-induced pain may be modulated by the 
stimulation of A 1 adenosine receptors because selective A 1 
but not A 2 agonists elicit the sympathoexcitatory response 
caused by the intracoronary infusion of adenosine. In hu- 
mans, bamiphylline, a selective antagonist of A l adenosine 
receptors (16), reduces the pain induced by intradermal 
injection of adenosine but not the A2-receptor-mediated 
cutaneous hyperemia, thus suggesting that A 1 receptors are 
involved in cutaneous nociception (17). 
To establish the role played by At adenosine receptors in 
mediating the muscular pain caused by adenosine, we studied 
the effects of bamiphylline on pain induced by the intrailiac 
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infusion of adenosine. After this preliminary study we then 
studied the effects of bamiphylline on cardiac pain and coro- 
nary vasodilation caused by the intracoronary infusion of 
adenosine. 
Methods  
Intrailiac study. Patients. A total of 20 consecutive pa- 
tients (17 men, 3 women; mean age 61 _ 10 years, range 43 to 
75 y) with uncomplicated stable angina who did not show any 
evidence of peripheral vascular disease (ankle-brachial index 
>1 assessed by vascular Doppler echocardiography) partici- 
pated in this study. During the hospital period, calcium chan- 
nel blocking and beta-adrenergic blocking agents were with- 
drawn 48 h before the study. Patients were also requested to 
abstain from xanthine-containing drugs and food and drink for 
at least 48 h before study. Patients with a history of glucose 
intolerance were excluded from the study. All patients gave 
written informed consent for participation i  the study, which 
was approved by the Institutional Ethics Committee in March 
1992. 
Study protocol At the end of routine cardiac catheteriza- 
tion, patients underwent heparinization (5,000 IU intrave- 
nously) and a randomized study of the algogenic effects of the 
intrailiac infusion of adenosine. In all patients adenosine was 
initially infused at increasing doses of 125, 250, 500, 1,000, 
2,000 t~g/min for periods of 3 rain each into the right external 
iliac artery through a 5F catheter, advanced through a 7F 
sheath positioned in the right femoral artery. At the onset of 
pain, adenosine infusion was continued to complete the infu- 
sion period of that particular dose and was then stopped. After 
10 min, patients were randomized to receive adenosine infu- 
sion at the same doses as those for the initial infusion after the 
intrailiac infusion of either injectable bamiphylline (bamiphyl- 
line hydrochloridum, 300 mg dissolved in 5 ml of 0.9% sodium 
chloride, Christiaens .a., Brussels, Belgium) at a dose of 
450 mg in 20 rain (10 patients) or vehicle (10 patients). The 
time to onset of pain (in seconds from the beginning of the 
infusion) and maximal pain severity, assessed by using a visual 
analog scale, were recorded after each adenosine infusion. 
Arterial blood pressure, obtained through the side port of the 
femoral sheath, and the standard 12 ECG leads were recorded 
continuously throughout the study. 
Intracoronary study. Fourteen patients (11 men, 3 women; 
mean age 55 _+ 12 years) with uncomplicated stable angina 
pectoris and significant left coronary atherosclerosis ( nternal 
diameter reduction ->50% by visual assessment i  the proximal 
two-thirds of at least one major epicardial vessel) participated 
in this study. No patient had a previous myocardial infarction. 
All patients had positive exercise test results for myocardial 
ischemia, with horizontal or downsloping ST segment depres- 
sion ->1.0 mm, and anginal pain. Four patients had a stenosis 
in the left anterior descending coronary artery, eight in the 
proximal circumflex artery and two in both arteries. All 
patients were normotensive, in sinus rhythm and without 
evidence of heart failure, cardiomyopathy or valvular disease. 
Patients with a history of glucose intolerance were excluded 
from the study. No patient had evidence of left ventricular 
hypertrophy or conduction defects that could interfere with 
interpretation of ST segment changes, and no patient was 
taking digitalis. During the hospital period, calcium channel 
blocking and beta-blockers were withdrawn 48 h before the 
study. Only sublingual nitroglycerin was permitted, and a 
minimum of 12 h were allowed to elapse before the procedure 
was begun if this drug was used. All patients were also 
requested to abstain from xanthine-containing drugs and food 
and drink for at least 48 h before study. All patients gave 
written informed consent for participation i  the study, which 
was approved by the Institutional Ethics Committee in January 
1993. 
Study protocol. On completion of the diagnostic anglo- 
grams for both coronary arteries, patients underwent hepa- 
rinization (5,000 IU intravenously), and the left coronary 
artery ostium was recannulated with an 8F left Judkins-style 
Doppler-tipped angiographic catheter (Kern technique) of the 
appropriate size (Cordis Corporation) for continuous monitor- 
ing of coronary blood flow velocity (20-MHz pulsed Doppler 
velocimeter, MDV-20, Millar Instruments, Inc.). The Judkins- 
style Doppler-tipped catheter is an 8F polyvinylchloride cath- 
eter with a 20-MHz ultrasound crystal positioned on the 
inferior edge of the distal tip (18). For accurate measurements 
the Judkins tip angle was positioned parallel to the left main 
coronary artery. Patients in whom it was not possible to obtain 
a satisfactory tip angle to record an appropriate flow signal 
were excluded from the study. After obtaining an adequate and 
stable Doppler signal, adenosine was infused into the left main 
coronary artery at increasing scalar doses of 108, 216, 432, 864, 
1,728/xg/min for periods of 2 min each until the appearance of
pain. At the onset of pain, adenosine infusion was continued to 
complete the infusion period of that particular dose and was 
then stopped. After 10 min, patients were randomized to 
receive adenosine infusion at the same doses as those for the 
initial adenosine infusion 5 rain after intravenous infusion of 
either injectable bamiphylline (300 mg in 20 min) (7 patients) 
or vehicle (7 patients). The time to pain onset (in seconds from 
the beginning of the infusion) and maximal pain severity 
assessed by using a visual analog scale were recorded after 
each adenosine infusion. Arterial blood pressure, obtained 
through the side port of the 8F femoral sheath, and the 
standard 12 ECG leads were continuously recorded through- 
out the study. The study was always completed within 60 min. 
Assessment of pain. At the beginning of each adenosine 
infusion, patients were informed that they might develop ain 
or other unpleasant symptoms. This information was not 
repeated uring adenosine infusions to avoid any potential 
bias. Patients were also instructed to report promptly the onset 
of pain and to record the maximal severity of the pain. 
Immediately after the test, while the patients were still in the 
catheterization laboratory, they were asked to report the 
maximal severity of pain experienced during both adenosine 
infusions on the same visual analog scale (19). To this end, the 
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Figure 1. Effects of bamiphylline and placebo n the 
time to pain onset during intrailiac infusion of aden- 
osine. Individual values and mean value - 1 SD are 
shown. 
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100-mm scale was marked from no symptoms to severe symp- 
toms. The scale was measured from 0 to the subject's mark in 
millimeters. All subjects, but not the testing personnel, had no 
knowledge of the substances infused. 
Statistical analysis. Statistical analysis of the hemody- 
namic data was performed using the Student t test for paired 
data. The Student test for paired data was used also to 
compare the time to pain onset. Pain severity was analyzed 
using the Wilcoxon signed rank test because this variable does 
not follow a normal distribution (19). Visual analog scale data 
are expressed as median and interquartile ranges. The remain- 
ing data are presented as mean value _ 1 SD. For the purpose 
of this study, p < 0.05 was considered statistically significant. 
Results 
Intrailiac study. Assessment ofmuscular pain. All patients 
experienced pain localized to the right leg during the first 
adenosine infusion. Thirteen patients described the pain as a 
feeling of heaviness, three as a cramp and four as tingling. No 
patient reported any symptom during intrailiac bamiphylline or 
placebo infusion. The highest dose of adenosine given before 
bamiphylline was 250/xg/min in three patients, 500/xg/min in 
six and 1,000/xg/min i  one. The highest dose of adenosine 
given after bamiphylline was 1,000/xg/min i four patients and 
2,000/xg/min i  six. After bamiphylline administration, three 
patients did not experience any pain at all, even during the 
infusion of the highest dose of adenosine. On average, bam- 
iphylline prolonged time to pain onset from 444 _+ 96 to 749 _+ 
120 s (p < 0.001); pain severity was reduced from 45 to 24 mm 
(p < 0.01). Conversely, after vehicle administration, the time 
to pain onset and pain severity did not change (428 -+ 112 vs. 
430 _ 104 s, p = 0.87 and 44 vs. 43 mm, p = 0.67, respectively) 
(Fig. 1 and 2). The highest dose of adenosine given before 
placebo was 250 txg/min in two patients, 500/xg/min in seven 
and 1,000/zg/min one. The highest dose of adenosine given 
mm 100 
Figure 2. Effects of bamiphylline and placebo on 
severity of pain during intrailiac infusion of adenosine. 
Individual values and median value with interquartile 
range are shown. 
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Figure 3. Effects of bamiphylline and placebo n the 
time to pain onset during intracoronary infusion of 
adenosine. Individual values and mean value _+ 1 SD 
are shown. 
after placebo was 250/zg/min i  three patients, 500/~g/min i  
four and 1,000/zg/min in three. 
Hemodynamic and ECG findings. Compared with baseline 
values, intraarterial infusion of bamiphylline or placebo did not 
produce any significant change in heart rate (70 _+ 9 vs. 69 -+ 
10 beats/rain, p = 0.20 and 68 + 8 vs. 70 _ 7 beats/rain, p = 
0.17, respectively) or in mean aortic pressure (103 -+ 15 vs. 
99 + 16 mm Hg, p = 0.06 and 102 _+ 10 vs. 103 _+ 12 mmHg, 
p = 0.76, respectively) compared with baseline values. 
Intracorouary study. Assessment of anginal pain. During 
adenosine infusion before bamiphylline or placebo administra- 
tion, all patients experienced pain similar to their habitual 
anginal pain. During intravenous infusion of bamiphylline, two 
patients complained of transient dizziness not associated to 
hemodynamic changes. No patient reported any symptom 
during placebo infusion. The highest dose of adenosine given 
before bamiphylline was 216/zg/min i one patient, 432/zg/min 
in two, 864 tzg/min in one and 1,728 in three. The highest dose 
of adenosine given after bamiphylline was 216/~g/min i  one, 
864/zg/min in two and 1,728/~g/min four. After bamiphyl- 
line administration, two patients did not experience any pain at 
all, even when the maximal dose of adenosine was infused. On 
average, bamiphylline prolonged time to pain onset from 
519 ___ 128 to 603 _+ 146 s (p < 0.01); pain severity was reduced 
from 58 to 28 mm (p < 0.02). By contrast, placebo adminis- 
tration did not affect either time to pain onset (542 _+ 87 vs. 
551 _+ 79 s, p = 0.14) or pain severity (55 vs. 50 ram, p = 0.61) 
(Fig. 3 and 4). The highest dose of adenosine given before 
placebo was 432/~g/min two patients, 864/~g/min two and 
1,728 /~g/min in three. The highest dose of adenosine given 
after placebo was 432/~g/min i  three patients, 864/xg/min i  
one and 1,728/zg/min in three. 
Coronary flow velocity findings. Compared with baseline 
values, intravenous infusion of bamiphylline or placebo did not 
produce any significant change in mean baseline coronary 
blood flow velocities (10 - 7 vs. 9.5 _+ 6 cm/s, p = 0.32 and 
mm 100.  
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Figure 4. Effects of bamiphylline and placebo n 
severity of pain during intracoronary infusion of aden- 
osine. Individual values and median value with inter- 
quartile range are shown. 
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Figure 5. Effects of bamiphylline on coronary 
blood flow velocity during intracoronary infu- 
sion of adenosine. Crosshatched bars = be- 
fore bamiphylline; hatched bars = after bam- 
iphylline. Numbers in boxes at the bottom of 
bars indicate number of patients who achieved 
that particular adenosine dose. Lines = SD. 
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10 _+ 6 vs. 9.2 _+ 6 cm/s, p = 0.36, respectively). Administration 
of bamiphylline and placebo did not affect he increase in mean 
coronary blood flow velocities when increasing doses of intra- 
coronary adenosine were infused (Fig. 5 and 6). Coronary 
blood flow velocities at the maximal adenosine dose that was 
tolerated both before and after bamiphylline were similar 
(47 + 22 vs. 49 _+ 24 cm/s, p = 0.36). Coronary blood flow 
velocities at the maximal adenosine dose that was tolerated 
both before and after placebo were also similar (40 + 20 vs. 
41 _+ 20 cm/s, p = 0.07). 
Hemodynamic and ECG findings. Intravenous infusion of 
bamiphylline or placebo did not produce any significant change 
in heart rate (68 _+ 7 vs. 68 + 8 beats/min, p -- 0.21 and 68 _+ 
5 vs. 65 + 7 beats/min, p = 0.14, respectively) or in systolic 
aortic pressure (135 + 18 vs. 132 _+ 10 mm Hg, p = 0.18 and 
131 + 12 vs. 132 _+ 8 mm Hg, p : 0.22, respectively) or 
diastolic aortic pressure (77 + 6 vs. 74 +_ 4 mm Hg, p = 0.17 
and 81 _+ 9 vs. 80 _+ 5 mm Hg, p = 0.24, respectively) compared 
with baseline values. During adenosine infusion, no patient 
developed ECG signs of myocardial ischemia. 
Discuss ion 
Present study. This study shows that in humans, bamiphyl- 
line, a selective antagonist of A] adenosine receptors, reduces 
both the muscular pain provoked by intrailiac adenosine 
infusion and the cardiac pain provoked by intracoronary 
adenosine infusion; yet, it does not affect adenosine-induced 
coronary vasodilation. These findings indicate that in humans, 
bamiphylline, at the dose used in this study, does not detect- 
ably block A 2 adenosine receptors and strongly suggest that the 
Figure 6. Effects of placebo n coronary blood 
flow velocity during intracoronary infusion of 
adenosine. Crosshatched bars = before pla- 
cebo; hatched bars = after placebo. Numbers 
in boxes at the botton of bars indicate number 
of patients who achieved that particular aden- 
osine dose, Lines = SD. 
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muscular and cardiac algogenic effects of adenosine are mainly 
mediated by A 1 receptors. 
Bamiphylline is the most selective At-adenosine receptor 
antagonist clinically available in Europe. In crude synaptic 
membranes prepared from rat brain, it displaces radioligands 
from A 1 adenosine receptors with a potency similar to that of 
8-phenil-theophylline, whereas it has a much lower potency on 
A 2 adenosine receptors (16). This results in a high degree of 
Al-receptor selectivity, indicated by a Az/A 1 ratio of 596. At 
the dose used in the present study, the mean plasma concen- 
tration of bamiphylline (-0.5.10 _5 tool/liter) displaces 80% of 
H-3 diethyl-8-phenilxanthine (an antagonist of A t adenosine 
receptors), 50% of H-3 cyclobexyladenosine (an agonist of A 1 
adenosine receptors) but only 5% of H-3 N-ethylcarboxamido- 
adenosine (an agonist of A 2 adenosine receptors). Thus, at the 
dose used in this study, bamiphylline results in a rather 
selective blockade of A 1 adenosine receptors. To our knowl- 
edge the Al-receptor bamiphylline selectivity has never been 
directly compared with that of some of the newest xanthine A1 
antagonists that have been developed in recent years. How- 
ever, the previous observation that bamiphylline does not 
suppress adenosine-induced cutaneous vasodilation, which is 
known to be mediated by vascular A 2 receptors, and the 
present observation that bamiphylline does not inhibit 
adenosine-induced coronary vasodilation, suggest that the 
selectivity of bamiphylline for A~ receptors, at the dose used in 
these investigations, is preserved. 
Previous studies. Experimental studies (15,20-22) have 
indicated that adenosine activates afferent nerves, and several 
clinical studies (1-5) have shown that adenosine is an impor- 
tant mediator of muscular and ischemic pain. In patients with 
coronary artery disease, tbeophylline, a nonselective antago- 
nist of adenosine receptors, reduces the severity of the anginal 
pain induced by intracoronary infusion of adenosine (2). 
Theophylline also completely abolishes adenosine-induced l g
pain (23). However, theophylline is a competitive nonselective 
antagonist of both A 1 and A 2 adenosine receptors (24), and 
therefore which receptor subtype mediates the algogenic ef- 
fects of adenosine cannot be determined. Previous tudies have 
suggested that the vascular and algogenic effects of adenosine 
might be mediated by different receptors. Indeed, monitoring 
of coronary sinus blood oxygen saturation, during intracoro- 
nary infusion of adenosine, showed that the doses that cause 
chest pain are higher than those that cause maximal coronary 
dilation (2,25). More recent experimental investigations ug- 
gest that adenosine-induced pain might be mediated by the 
A 1-adenosine receptor subtype because in dogs with sinoaortic 
denervation and vagotomy, adenosine has been shown to 
activate cardiac sympathetic afferent fibers; this sympathoex- 
citatory reflex is elicited by selective A 1 but not A 2 adenosine 
agonists (15). Finally, in humans, bamiphylline reduces the 
pain induced by intradermal injection of adenosine but not the 
A2-receptor-mediated adenosine-induced cutaneous hypere- 
mia, thus suggesting that A~ receptors are involved in cutane- 
ous nociception (17). The present study confirms and expands 
these observations by showing that in humans, the muscular 
and cardiac algogenic effects of adenosine also are mediated by 
A 1 adenosine receptors. 
Study limitations. Critical to our study was the evaluation 
of cardiac pain. The assessment of pain using a visual analog 
scale represents a well established and accepted method for 
evaluation of pain perception (19). The reliability of this 
method in assessing pain severity is supported by the observa- 
tion that in this study adenosine-induced pain severity was 
similar before and after placebo administration, similar to 
results reported in a previous tudy (5). In the present study, 
the testing personnel had knowledge of the infused materials. 
However, the greatest care was taken to follow a very rigid 
protocol to avoid any potential bias. To this end, all patients 
were reminded that they could develop symptoms at the 
beginning of each infusion only, and this information was not 
repeated uring the infusion. Furthermore, the patients them- 
selves, who had no knowledge of the infused substances, 
marked the visual analog scale. Finally, we failed to find any 
effect of bamiphylline on the response of coronary blood flow 
to adenosine. The power of the study in the assessment of this 
effect of bamiphylline was low mainly because of the small 
number of patients. However, even if an increased number of 
patients proved that the observed small difference is statisti- 
cally significant, it would not be relevant from a biologic and 
clinical standpoint. Furthermore, in the same patient bam- 
iphylline significantly reduced the algogenic effects of adeno- 
sine, thus suggesting that antagonism by bamiphylline of the 
algogenic effects of adenosine is more relevant than the 
possible antagonism of the effects of adenosine on the coro- 
nary circulation. 
Conclusions. In patients with angina pectoris, bamiphyl- 
line, a selective antagonist of A a adenosine receptors, reduces 
both muscular pain caused by intrailiac adenosine infusion and 
cardiac pain induced by intracoronary adenosine infusion. 
These findings indicate that in humans, bamiphylline, at the 
dose used in this study, does not detectably block vascular 
A2-receptor-mediated adenosine ffects and suggest that the 
muscular and cardiac algogenic effects of adenosine are mainly 
mediated by A 1 receptors. 
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